One Biosciences Secures Major Funding for Clinical Advancements
In a remarkable development in the field of precision oncology, One Biosciences has announced a significant financing achievement of €15 million. This funding aims to propel the company forward in establishing the clinical utility of OneMap™, an innovative platform utilizing artificial intelligence for single cell transcriptomic analysis.
Strategic Goals for Investment
The new capital will primarily support the expansion of OneMap™, enhancing its capability to guide treatment decisions, improve patient selection for therapies, develop new treatment options, and refine the conduct of clinical trials. The advancement of this cutting-edge technology is expected to reshape the landscape of patient care and cancer treatment.
Support from Leading Investors
This financing round, orchestrated by prominent investors including Redmile Group and Blast, has also attracted contributions from notable firms such as Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. With this influx, One Biosciences has successfully raised over €20 million to date, signaling strong confidence from the investment community.
The Impact of OneMap™
One Biosciences specializes in generating detailed functional profiles of cancerous tumors. This innovative approach allows for valuable insights that can drive improved clinical decision-making and optimize patient care. The investment will expedite the development of OneMap™ while facilitating deeper collaborations with pharmaceutical and biotechnology companies.
Expert Insights on One Biosciences' Mission
Hedi Ben Brahim, the CEO of One Biosciences, emphasized the company's commitment to advancing cancer care through their groundbreaking technology. He stated, "This funding empowers us to translate our transformative single-cell insights into real-time applications that can significantly inform clinicians’ decisions, enhance patient treatment, and expedite the drug development process."
Building on Expertise
Dr. Céline Vallot, one of the founders and an esteemed leader at Curie Institute, remarked on the unique capabilities of their AI algorithms. She noted that the funding would not only enhance their technological infrastructure but also justify their predictive capabilities regarding patient responses to various oncological treatments derived from clinical specimens.
Contributions to Cancer Therapy Innovations
Dr. Mehdi Touat, an influential figure at Assistance Publique - Hôpitaux de Paris, highlighted the limitations of existing next-generation sequencing profiling. He asserted that while notable progress has been made in oncology, the real benefits have yet to reach the majority of patients. Clinical grade single cell profiling could unlock the next wave of advancements in diagnostics and therapies.
About One Biosciences
Founded in 2020 by Dr. Céline Vallot in collaboration with Home Biosciences, One Biosciences is committed to pioneering advancements in single cell transcriptomic oncology solutions. Their vision is to support clinicians in identifying the most effective treatments for cancers by decoding the complex heterogeneity of tumors from routinely collected clinical samples. Additionally, their innovations aim to enhance clinical trial outcomes for pharmaceutical companies.
One Biosciences has established partnerships with leading institutions such as Curie Institute, Gustave Roussy Institute, and Assistance Publique - Hôpitaux de Paris, while benefitting from the endorsements of Medicen, PSCC, and Matwin. Their robust financial backing comprises support from Bpifrance, Région Ile de France, France 2030, and a consortium of venture capitalists including Redmile Group, Blast, and others.
Frequently Asked Questions
What is OneMap™?
OneMap™ is an AI-driven platform for single cell transcriptomic profiling that aids in making informed decisions regarding cancer treatments.
Who are the key investors in One Biosciences' funding round?
The funding was led by Redmile Group and Blast, along with contributions from several other notable investment firms.
How will the funding be used?
The investment will support the clinical development of OneMap™ and expand partnerships within the pharmaceutical and biotech sectors.
What is the mission of One Biosciences?
One Biosciences aims to improve cancer patient care by providing precise insights into tumor profiles, thereby enhancing treatment effectiveness.
When was One Biosciences founded?
One Biosciences was founded in 2020 by Dr. Céline Vallot and is spearheading innovative solutions in the oncology technology space.
